Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX Other stock markets 03:56:28 2024-04-24 pm EDT			5-day change	1st Jan Change
67.02 ^USD	-0.01%		-0.09%	-17.45%

07:28pm	HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	MT
Apr. 23	Argus Cuts Price Target on Gilead Sciences to $75 From $85	MT

Evolution of the average Target Price on Gilead Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0b5fc091952043e0bfd.kvuxCmZIZiwOyyjWeSInn73GreA54RnUrKpbJ72FmHc.3I78eyEuL0pIik2AP0li8eeeldcPqUGt9JgEEujt_Eag1t04Ky4iSUX_HA~08c9243633df637b16bf82e1fcd68547

Analyst Recommendations on Gilead Sciences, Inc.

HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	01:28pm	MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85	Apr. 23	MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating	Apr. 22	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89	Apr. 19	MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79	Apr. 19	MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating	Apr. 17	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	Apr. 15	MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating	Apr. 09	MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating	Mar. 04	MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating	Feb. 22	MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91	Feb. 22	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	Feb. 16
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating	Feb. 14	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	Feb. 13	MT
Oppenheimer Cuts Gilead Sciences Price Target to $105 From $115, Maintains Outperform Rating	Feb. 12	MT
UBS Adjusts Gilead Sciences Price Target to $81 From $80, Maintains Neutral Rating	Feb. 08	MT
Fed officials fail to convince investors, who are focused on earnings	Feb. 07
Wall St set for higher open as earnings, rate outlook in focus	Feb. 07	RE
Piper Sandler Adjusts Gilead Sciences Price Target to $95 From $100, Maintains Overweight Rating	Feb. 07	MT
TD Cowen Adjusts Gilead Sciences Price Target to $90 From $95, Maintains Outperform Rating	Feb. 07	MT
Cantor Fitzgerald Adjusts Gilead Sciences Price Target to $78 From $80, Maintains Neutral Rating	Feb. 07	MT
Leerink Partners Adjusts Gilead Sciences Price Target to $79 From $87, Maintains Market Perform Rating	Feb. 07	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $84 From $90, Keeps Equalweight Rating	Feb. 07	MT
RBC Cuts Price Target on Gilead Sciences to $76 From $78, Notes Core Business Headwinds, Pipeline Setbacks; Keeps Sector Perform Rating	Feb. 07	MT
That's good enough for investors	Feb. 06

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

67.03 USD

Average target price

84.95 USD

Spread / Average Target

+26.73%

High Price Target

121 USD

Spread / Highest target

+80.52%

Low Price Target

69 USD

Spread / Lowest Target

+2.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Gilead Sciences, Inc.

Argus
Cantor Fitzgerald
BMO Capital
Leerink Partners
UBS
Goldman Sachs
Morgan Stanley
Wells Fargo Securities
Mizuho Securities
Truist Securities
RBC Capital Markets
Oppenheimer
TD Cowen
Piper Sandler
Barclays
Deutsche Bank Securities
BofA Securities
HSBC
SVB Securities LLC
Cowen
Maxim
JPMorgan Chase
SVB Leerink
Credit Suisse
Bernstein
Redburn
DZ BANK	Elmar Kraus

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar